Post by VVMF

VVMF - Viral Vector Manufacturing Facility will be attending the American Society of Gene & Cell Therapy 𝟮𝟬𝟮𝟲 in Boston, 11–15 May. Meet the leaders behind Australia’s only viral vector manufacturing facility. VVMF continues to build Australia’s clinical‑ and commercial‑scale capability in viral vector manufacturing, supporting innovators developing cell and gene therapies globally. Our CEO, Stephen Thompson, and Deputy Chief Technology Officer, Vasily M., will be joining the global CGT community in Boston and look forward to sharing how VVMF supports 𝗟𝗩 and 𝗔𝗔𝗩 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 from early clinical development through to commercial readiness. Learn more about our: ✔️ Advanced Process and analytical development ✔️ End‑to‑end viral vector manufacturing ✔️ Wrap‑around services and strategic advice to help you leverage Australia’s thriving biotech ecosystem The 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮𝗻 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 includes access to the 𝗥&𝗗 𝗧𝗮𝘅 𝗜𝗻𝗰𝗲𝗻𝘁𝗶𝘃𝗲, offering a tax rebate of up to 43.5% — a powerful boost for biotech innovation. 📧 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀: [email protected] We look forward to connecting in Boston. #ASGCT2026 #CellAndGeneTherapy #GeneTherapy #ViralVectors #CDMO #VVMF #AustralianAdvantage #UnlockingtheFutureofMedicine Anita van der Meer Australian Trade and Investment Commission (Austrade) Investment NSW AusBiotech Ann Damien Steven Spezza Hanh Hoang Shaun M. Hayley van der Meer